AnaptysBio's (ANAB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• AnaptysBio's stock has been reaffirmed with a "Sell (D-)" rating by Weiss Ratings, indicating a negative outlook from these analysts.
• JPMorgan Chase & Co. raised their price target for AnaptysBio from $42.00 to $80.00, while several other brokerages provided various ratings, reflecting a mixed view on the stock's potential.
• The company's recent quarterly earnings showed a loss of ($1.34) EPS, surpassing estimates, with a significant revenue of $22.26 million against expectations of $11.55 million.

AnaptysBio (NASDAQ:ANAB - Get Free Report)'s stock had its "sell (d-)" rating reiterated by research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other brokerages have also commented on ANAB. JPMorgan Chase & Co. boosted their price target on AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a research note on Thursday, July 24th. HC Wainwright boosted their price target on AnaptysBio from $38.00 to $59.00 and gave the company a "buy" rating in a report on Tuesday, September 30th. Wedbush restated an "outperform" rating and set a $45.00 price objective on shares of AnaptysBio in a report on Tuesday, September 30th. Finally, UBS Group reaffirmed a "neutral" rating and set a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $48.75.

AnaptysBio Price Performance

Shares of ANAB traded up $1.96 during midday trading on Wednesday, reaching $31.83. 665,987 shares of the stock were exchanged, compared to its average volume of 738,724. The business's 50-day moving average price is $22.57 and its 200 day moving average price is $22.05. AnaptysBio has a twelve month low of $12.21 and a twelve month high of $36.54. The company has a market capitalization of $891.24 million, a price-to-earnings ratio of -7.10 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.50) by $0.16. The firm had revenue of $22.26 million for the quarter, compared to analysts' expectations of $11.55 million. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. As a group, equities research analysts expect that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. US Bancorp DE increased its stake in shares of AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 979 shares during the period. Farther Finance Advisors LLC grew its position in AnaptysBio by 9,778.9% in the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after buying an additional 1,858 shares during the last quarter. Tower Research Capital LLC TRC grew its position in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after buying an additional 1,377 shares during the last quarter. Osaic Holdings Inc. grew its position in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after buying an additional 2,326 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new position in AnaptysBio in the first quarter worth approximately $113,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.